322 related articles for article (PubMed ID: 30622541)
1. Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80.
Cassady K; Martin PJ; Zeng D
Front Immunol; 2018; 9():3061. PubMed ID: 30622541
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells.
Ni X; Song Q; Cassady K; Deng R; Jin H; Zhang M; Dong H; Forman S; Martin PJ; Chen YZ; Wang J; Zeng D
J Clin Invest; 2017 May; 127(5):1960-1977. PubMed ID: 28414296
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 serves as a double agent in separating GVL from GVHD.
Brennan TV; Yang Y
J Clin Invest; 2017 May; 127(5):1627-1630. PubMed ID: 28414300
[TBL] [Abstract][Full Text] [Related]
4. Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity.
Song Q; Nasri U; Nakamura R; Martin PJ; Zeng D
Front Immunol; 2022; 13():907673. PubMed ID: 35677056
[TBL] [Abstract][Full Text] [Related]
5. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
Fowler DH; Gress RE
Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.
Koestner W; Hapke M; Herbst J; Klein C; Welte K; Fruehauf J; Flatley A; Vignali DA; Hardtke-Wolenski M; Jaeckel E; Blazar BR; Sauer MG
Blood; 2011 Jan; 117(3):1030-41. PubMed ID: 21063028
[TBL] [Abstract][Full Text] [Related]
7. Donor T cell STAT3 deficiency enables tissue PD-L1-dependent prevention of graft-versus-host disease while preserving graft-versus-leukemia activity.
Li Q; Wang X; Song Q; Yang S; Wu X; Yang D; Marié IJ; Qin H; Zheng M; Nasri U; Kong X; Wang B; Lizhar E; Cassady K; Tompkins J; Levy D; Martin PJ; Zhang X; Zeng D
J Clin Invest; 2023 Aug; 133(15):. PubMed ID: 37526084
[TBL] [Abstract][Full Text] [Related]
8. Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease.
Choi J; Cooper ML; Staser K; Ashami K; Vij KR; Wang B; Marsala L; Niswonger J; Ritchey J; Alahmari B; Achilefu S; Tsunoda I; Schroeder MA; DiPersio JF
Leukemia; 2018 Nov; 32(11):2483-2494. PubMed ID: 29691471
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of T-cell-suppressive PD-L1
Baur R; Karl F; Böttcher-Loschinski R; Stoll A; Völkl S; Gießl A; Flamann C; Bruns H; Schlötzer-Schrehardt U; Böttcher M; Schewe DM; Fischer T; Jitschin R; Mackensen A; Mougiakakos D
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36898735
[TBL] [Abstract][Full Text] [Related]
10. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
Chang YJ; Zhao XY; Huang XJ
Front Immunol; 2018; 9():3041. PubMed ID: 30619371
[TBL] [Abstract][Full Text] [Related]
11. Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity.
Song Q; Wang X; Wu X; Qin H; Li Y; Riggs AD; Martin PJ; Chen YZ; Zeng D
Blood; 2021 Apr; 137(16):2243-2255. PubMed ID: 33511398
[TBL] [Abstract][Full Text] [Related]
12. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
13. Prevention of GVHD without losing GVL effect: windows of opportunity.
Zhang P; Chen BJ; Chao NJ
Immunol Res; 2011 Apr; 49(1-3):49-55. PubMed ID: 21136200
[TBL] [Abstract][Full Text] [Related]
14. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality.
Saha A; O'Connor RS; Thangavelu G; Lovitch SB; Dandamudi DB; Wilson CB; Vincent BG; Tkachev V; Pawlicki JM; Furlan SN; Kean LS; Aoyama K; Taylor PA; Panoskaltsis-Mortari A; Foncea R; Ranganathan P; Devine SM; Burrill JS; Guo L; Sacristan C; Snyder NW; Blair IA; Milone MC; Dustin ML; Riley JL; Bernlohr DA; Murphy WJ; Fife BT; Munn DH; Miller JS; Serody JS; Freeman GJ; Sharpe AH; Turka LA; Blazar BR
J Clin Invest; 2016 Jul; 126(7):2642-60. PubMed ID: 27294527
[TBL] [Abstract][Full Text] [Related]
15. Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT.
Mammadli M; Huang W; Harris R; Sultana A; Cheng Y; Tong W; Pu J; Gentile T; Dsouza S; Yang Q; Bah A; August A; Karimi M
Front Immunol; 2020; 11():593863. PubMed ID: 33324410
[TBL] [Abstract][Full Text] [Related]
16. The Role of Co-stimulatory/Co-inhibitory Signals in Graft-vs.-Host Disease.
Kumar S; Leigh ND; Cao X
Front Immunol; 2018; 9():3003. PubMed ID: 30627129
[TBL] [Abstract][Full Text] [Related]
17. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
Front Immunol; 2021; 12():785774. PubMed ID: 34987512
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 Ameliorates Murine Acute Graft-Versus-Host Disease by Suppressing Effector But Not Regulatory T Cells Function.
Tang L; Ma S; Gong H; Wang J; Xu Y; Wu D; Sun A
Arch Immunol Ther Exp (Warsz); 2019 Jun; 67(3):179-187. PubMed ID: 30927016
[TBL] [Abstract][Full Text] [Related]
19. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.
Saha A; Aoyama K; Taylor PA; Koehn BH; Veenstra RG; Panoskaltsis-Mortari A; Munn DH; Murphy WJ; Azuma M; Yagita H; Fife BT; Sayegh MH; Najafian N; Socie G; Ahmed R; Freeman GJ; Sharpe AH; Blazar BR
Blood; 2013 Oct; 122(17):3062-73. PubMed ID: 24030385
[TBL] [Abstract][Full Text] [Related]
20. Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice.
Asakura S; Hashimoto D; Takashima S; Sugiyama H; Maeda Y; Akashi K; Tanimoto M; Teshima T
J Clin Invest; 2010 Jul; 120(7):2370-8. PubMed ID: 20530875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
